Brokerages Set Haemonetics Co. (NYSE:HAE) PT at $101.22

Haemonetics Co. (NYSE:HAE - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $101.22.

A number of brokerages have issued reports on HAE. Bank of America cut shares of Haemonetics from a "neutral" rating to an "underperform" rating and cut their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. JMP Securities dropped their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. Barrington Research lowered their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Finally, Needham & Company LLC lowered their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th.

Institutional Trading of Haemonetics

Several hedge funds and other institutional investors have recently bought and sold shares of HAE. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics during the 4th quarter valued at approximately $25,000. Covestor Ltd boosted its position in Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares during the period. Whittier Trust Co. bought a new position in Haemonetics during the 4th quarter worth $62,000. Parkside Financial Bank & Trust increased its position in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the period. Finally, AlphaQuest LLC lifted its stake in Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after buying an additional 1,826 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

HAE traded up $1.29 during trading on Friday, hitting $63.93. 153,415 shares of the stock were exchanged, compared to its average volume of 687,412. Haemonetics has a 1-year low of $55.30 and a 1-year high of $97.97. The firm has a market capitalization of $3.21 billion, a P/E ratio of 25.15, a PEG ratio of 1.11 and a beta of 0.41. The stock has a fifty day moving average price of $62.80 and a two-hundred day moving average price of $72.02. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, sell-side analysts predict that Haemonetics will post 4.55 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.